Latest Breaking News On - Erythropoiesis stimulating agents - Page 4 : comparemela.com

Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3

- Data support NDA submission which is on track for June 2023 to support potential U.S. commercial launch in first half of 2024 . | May 25, 2023

United statesAmericaAmericanAmer methqal zeidanFaye fellerAmerican society of clinical oncologyGeron corporation nasdaqYale school of medicineDrug administrationLinkedinGeron corporationClinical oncologyNew drug applicationExecutive vice presidentChief medical officerPlacebo controlled study

Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3

Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAmericaAmericanAaron feingoldAmer methqal zeidanFaye fellerGeron corporation nasdaqGeron corporationDrug administrationYale school of medicineAmerican society of clinical oncologyLinkedinExchange commissionWall streetClinical oncologyNew drug application

Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3

Longer follow-up data for 1-year transfusion independence in IMerge Phase 3, which demonstrated statistically significant and clinically meaningful continuous, durable efficacy Strong. | May 11, 2023

GermanyParisFrance generalFranceLeipzigSachsenUnited statesAmericaFaye fellerNicolas chatainMikkael sekeresNicolas chapuisValeria santiniUwe platzbeckerUniversity hospital of leipzigDrug administration

Geron Corporation: Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3

Longer follow-up data for 1-year transfusion independence (TI) in IMerge Phase 3, which demonstrated statistically significant and clinically meaningful continuous, durable efficacy Strong

ParisFrance generalFranceGermanyLeipzigSachsenUnited statesAmericaNicolas chatainFaye fellerUwe platzbeckerValeria santiniKaplan meierAaron feingoldMikkael sekeresNicolas chapuis

Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial

Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

ChicagoIllinoisUnited statesAmericaAmericanAmer methqal zeidanAaron feingoldGeron corporation nasdaqExchange commissionDrug administrationGeron corporationYale school of medicineLinkedinAmerican society of clinical oncologyClinical oncologyPlacebo controlled study